Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-12.74 Insider Own6.97% Shs Outstand1.24M Perf Week-11.18%
Market Cap12.19M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.23M Perf Month-15.82%
Income-16.25M PEG- EPS next Q- Inst Own35.74% Short Float1.38% Perf Quarter-46.43%
Sales40.93M P/S0.30 EPS this Y- Inst Trans-77.13% Short Ratio1.16 Perf Half Y-30.08%
Book/sh17.76 P/B0.52 EPS next Y- ROA-29.09% Short Interest0.02M Perf Year-87.17%
Cash/sh14.45 P/C0.64 EPS next 5Y- ROE-86.86% 52W Range9.31 - 73.60 Perf YTD-36.57%
Dividend Est.- P/FCF- EPS past 5Y11.57% ROI-73.99% 52W High-87.45% Beta0.68
Dividend TTM- Quick Ratio3.92 Sales past 5Y15.45% Gross Margin94.47% 52W Low-0.81% ATR (14)0.53
Dividend Ex-Date- Current Ratio3.92 EPS Y/Y TTM71.38% Oper. Margin-13.77% RSI (14)28.36 Volatility5.28% 4.46%
Employees50 Debt/Eq0.00 Sales Y/Y TTM142.89% Profit Margin-39.71% Recom1.67 Target Price560.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q72.06% Payout- Rel Volume0.76 Prev Close9.70
Sales Surprise399.00% EPS Surprise131.91% Sales Q/Q-97.26% Earnings- Avg Volume14.66K Price9.23
SMA20-10.11% SMA50-18.60% SMA200-41.87% Trades Volume11,093 Change-4.79%
Date Action Analyst Rating Change Price Target Change
Mar-13-20Upgrade Robert W. Baird Neutral → Outperform $5
Jul-30-19Downgrade Robert W. Baird Outperform → Neutral
May-14-19Initiated Robert W. Baird Outperform $5
Mar-19-18Initiated Jefferies Buy $12
Mar-19-18Initiated Evercore ISI Outperform $13
Jan-16-18Reiterated H.C. Wainwright Buy $9 → $12
May-30-17Initiated Rodman & Renshaw Buy $9
Aug-05-16Resumed ROTH Capital Buy
Aug-12-15Initiated JMP Securities Mkt Outperform
Jul-27-15Initiated Oppenheimer Outperform $8
May-17-24 02:52PM
May-15-24 05:43PM
Apr-19-24 12:10PM
Mar-27-24 08:00AM
Nov-14-23 05:36PM
12:00PM Loading…
Sep-25-23 12:00PM
Aug-24-23 12:32PM
Aug-23-23 12:00PM
Aug-17-23 08:00AM
Jul-19-23 02:02PM
Jul-18-23 01:59PM
Jul-17-23 07:29AM
Jun-23-23 10:50AM
07:00AM Loading…
Jun-21-23 07:00AM
Jun-11-23 10:28AM
Jun-02-23 04:30PM
May-22-23 08:00AM
May-21-23 08:00AM
May-15-23 06:07AM
May-11-23 01:41PM
May-10-23 08:15AM
May-05-23 06:41AM
May-04-23 08:00AM
May-02-23 04:30PM
Apr-17-23 08:00AM
Apr-01-23 12:47PM
Mar-31-23 06:10AM
05:00PM Loading…
Mar-29-23 05:00PM
Mar-24-23 05:00PM
Feb-19-23 07:39AM
Feb-14-23 05:40AM
Jan-17-23 07:10AM
Jan-10-23 08:00AM
Dec-21-22 06:01AM
Nov-23-22 08:00AM
Nov-09-22 08:00AM
Nov-02-22 08:35AM
Nov-01-22 09:15AM
Oct-26-22 08:00AM
Sep-12-22 08:03AM
Sep-08-22 04:01PM
Aug-24-22 10:34AM
Aug-10-22 06:20AM
Aug-04-22 02:03PM
Jul-28-22 07:20AM
Jul-14-22 06:29AM
Jun-02-22 08:00AM
May-18-22 09:35AM
May-16-22 09:35AM
May-11-22 08:45AM
May-04-22 08:00AM
Apr-15-22 11:00AM
Apr-09-22 06:00AM
Apr-08-22 06:15AM
Apr-05-22 12:00PM
Mar-04-22 04:00PM
Mar-01-22 11:05AM
Feb-28-22 09:25AM
Feb-23-22 08:00AM
Feb-04-22 08:58AM
Jan-28-22 08:00AM
Jan-27-22 06:23PM
Jan-16-22 10:30AM
Jan-14-22 08:00AM
Jan-03-22 07:00AM
Dec-15-21 12:53PM
Dec-06-21 09:33AM
Nov-11-21 08:05AM
Nov-08-21 08:00AM
Nov-02-21 09:05AM
Oct-26-21 08:00AM
Oct-14-21 10:00AM
Oct-06-21 08:00AM
Sep-09-21 08:00AM
Sep-08-21 10:31AM
Aug-27-21 10:40AM
Aug-24-21 09:00AM
Aug-06-21 09:42AM
Aug-04-21 09:25AM
Aug-03-21 08:00AM
Jul-28-21 08:00AM
Jun-30-21 08:31AM
Jun-25-21 09:24AM
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.